Page 3 - Moha El News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Globe and Mail Jameson Berkow Published March 2, 2021 Moha El-Jaw/iStockPhoto / Getty Images Could the burgeoning psychedelics sector end up spawning a major stock rally that could dwarf the cannabis-driven market mayhem of the past decade? According to Maruf Raza, a partner and national director of public companies at MNP LLP in Toronto, “From a market perspective, you could argue the blue-sky opportunity for psychedelics is far, far greater [than for cannabis].” Mr. Raza is part of a growing group of market watchers expecting vast sums of money to pour into companies studying psilocybin, ketamine, LSD and other so-called “hard drugs” for medical purposes. But because the nascent sector is largely organized around disrupting the global anti-depressant market, which is worth tens of billions of dollars annually to pharmaceutical giants, investors see less policy risk.

City ofUnited kingdomMoha elMaruf razaBrandon roopTatiana zdybPatrick moherSteve hawkinsExchange on janToronto stock exchangeHorizons etfs management canada incHorizons marijuana life sciencesMicrodose psychedelicHorizons psychedelic stock indexMicrodose psychedelic insightsGlobe advisor